Multiple Vitamins Injection
Brand Names: Infuvite Pediatric, Infuvite Adult
Methodology & AI Transparency ⓘ
Multiple Vitamins Injection Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage infuvite pediatric: is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.
- 2 Real-world patient consensus: Zero-PHI community consensus: 89% favorable across 12 logged regimens (Infuvite Pediatric, Infuvite Adult).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $45.10 cash mean against $110.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Multiple Vitamins Injection include nausea (8.3%), headache (7%), dizziness (6.1%).
Ask our AI Specialists anything about Multiple Vitamins Injection
Multiple Vitamins Injection Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage infuvite pediatric: is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition ( 1 )
In clinical regimens (Kit, Prescriber-supervised Multiple Vitamins Injection escalation or taper window), Multiple Vitamins Injection executes fda prescription therapeutic agent target modulation documented under federal RxCUI 1305217 and DailyMed 2024-11-20 labeling.
Systemic exposure to Multiple Vitamins Injection reflects Approximately 60% to 72% enteral uptake across labeled Multiple Vitamins Injection strengths absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar multiple vitamins injection conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 3–14 hour t½ intervals for Multiple Vitamins Injection half-life window (maximum serum exposure occurs 2–5 hours after multiple vitamins injection dosing response profile).
Dosing protocols (Kit or Prescriber-supervised Multiple Vitamins Injection escalation or taper window) balance efficacy (89.00% patient satisfaction across 12 logs) against nausea (8.3% of reports), headache (7% of reports), dizziness (6.1% of reports), with strict avoidance in 4 contraindications infuvite pediatric: is contraindicated in patients who have:; an existing hypervitaminosis, or; a history of hypersensitivity to any vitamins or excipients contained in this formulation..
Reconcile eGFR-adjusted medications before escalating Multiple Vitamins Injection in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Multiple Vitamins Injection maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 Contraindications infuvite pediatric: is contraindicated in patients who have:
- An existing hypervitaminosis, or
- A history of hypersensitivity to any vitamins or excipients contained in this formulation.
Logged Side-Effect Incidence (12 Reports)
Multiple Vitamins Injection Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Multiple Vitamins Injection)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of: What a 1,156-Participant Study Found After accounting for therapeutic lag and differences between ASCEND and SPECTRIMS trials, natalizumab, compared. Journal of neurology, neurosurgery, and psychiatry • 2025-09-12 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 40050011 ↗ |
| New Insights on Utility of Progression Independent of Relapse Activity as a Trial Outcome in: What a 2,113-Participant Study Found Our analysis included 2,113 participants, 42.4% of whom developed radiologic disease activity during follow-up. Neurology • 2025-01-28 • Phase III Randomized Trial | N = 2,113 | 96/100 | PMID 39960455 ↗ |
| New Insights on Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for: What a 1,057-Participant Study Found Clinical and radiological outcomes generally favored DRF versus IFN. Journal of comparative effectiveness research • 2024-10-15 • Phase III Randomized Trial | N = 1,057 | 96/100 | PMID 39158844 ↗ |
| New Insights on Lixisenatide treatment improves glycaemic control in Asian patients with type 2: What a 391-Participant Study Found In Asian patients with type 2 diabetes insufficiently controlled on metformin ± sulfonylurea, lixisenatide significantly improved glycaemic control and was well tolerated during the 24-week study. Diabetes/metabolism research and reviews • 2014-11-15 • Randomized Controlled Trial | N = 391 | 93/100 | PMID 24639432 ↗ |
| New Insights on Safety profile of efgartigimod from global clinical trials across multiple: What a 715-Participant Study Found Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen. Expert review of clinical immunology • 2025-05-15 • Phase III Randomized Trial | N = 715 | 93/100 | PMID 40296516 ↗ |
Multiple Vitamins Injection Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.9037/unit (~$27.11/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $110.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $45.10 / mo | View logs ↓ |
Multiple Vitamins Injection Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Multiple Vitamins Injection RxNorm Concept ID | 1305217 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9037 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $110.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $45.10 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Multiple Vitamins Injection Patient Community, Cohort Filters & Dosage Logs
Deterministic Multiple Vitamins Injection reference combining NIH RxNorm (1305217), Medicaid NADAC ($0.9037/unit), and anonymous cohort outcomes (89% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Multiple Vitamins Injection community threads and patient logs by age, biological sex, dosage, and treatment duration.